AlloVir, Inc. (NASDAQ:ALVR) CEO Sells $19,096.56 in Stock

AlloVir, Inc. (NASDAQ:ALVR – Get Rating) CEO Diana Brainard sold 4,536 shares of the firm’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $4.21, for a total value of $19,096.56. Following the completion of the transaction, the chief executive officer now owns 916,628 shares of the company’s stock, valued at approximately $3,859,003.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Diana Brainard also recently made the following trade(s):

• On Wednesday, April 19th, Diana Brainard sold 8,408 shares of AlloVir stock. The shares were sold at an average price of $3.71, for a total value of $31,193.68.

AlloVir Trading Up 1.9 %

Shares of NASDAQ:ALVR opened at $4.19 on Monday. The stock’s 50-day moving average price is $4.07 and its two-hundred day moving average price is $5.53. AlloVir, Inc. has a 12-month low of $3.17 and a 12-month high of $10.29. The firm has a market cap of $392.14 million, a price-to-earnings ratio of -2.10 and a beta of 0.72.

Institutional Trading of AlloVir

A number of hedge funds have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC boosted its stake in AlloVir by 33.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,210 shares of the company’s stock worth $37,000 after buying an additional 1,300 shares during the last quarter. Ensign Peak Advisors Inc boosted its stake in AlloVir by 27.0% in the 3rd quarter. Ensign Peak Advisors Inc now owns 7,300 shares of the company’s stock worth $58,000 after buying an additional 1,550 shares during the last quarter. Alliancebernstein L.P. boosted its stake in AlloVir by 6.3% in the 3rd quarter. Alliancebernstein L.P. now owns 28,500 shares of the company’s stock worth $225,000 after buying an additional 1,700 shares during the last quarter. Swiss National Bank boosted its stake in AlloVir by 2.7% in the 4th quarter. Swiss National Bank now owns 112,300 shares of the company’s stock worth $576,000 after buying an additional 2,900 shares during the last quarter. Finally, PDT Partners LLC boosted its stake in AlloVir by 10.3% in the 2nd quarter. PDT Partners LLC now owns 33,315 shares of the company’s stock worth $130,000 after buying an additional 3,117 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ALVR shares. Morgan Stanley decreased their price objective on AlloVir from $27.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, January 27th. SVB Leerink decreased their price objective on AlloVir from $25.00 to $19.00 and set an “outperform” rating on the stock in a research note on Monday, January 23rd. Finally, SVB Securities increased their price objective on AlloVir from $16.00 to $19.00 in a research note on Wednesday, April 26th.

AlloVir Company Profile

(Get Rating)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.